AAV virus capsid
Biotech

Vertex discontinues AAV research for gene therapies

Despite the shift away from AAVs, a company spokesperson affirmed that Vertex’s “commitment to cell and genetic therapies remains strong.”
Darren Incorvaia May 2, 2025 6:22pm
Concept of loss of money downward arrow made of dollar banknotes on white background

'Too big and unfocused': Trump slashes NIH budget by $18B

May 2, 2025 2:42pm
Monocled cobra

18 years of self-inflicted snakebites lead to new antivenom

May 2, 2025 2:10pm
HistoSonics Edison

HistoSonics considering a sale to major medtechs: report

May 2, 2025 11:30am
finch canary cage free bird release

FDA lifts hold on Amgen's phase 1 obesity study

May 2, 2025 10:10am
London Cancer Hub

UK unveils £1B plan to become leading cancer research hub

May 2, 2025 9:25am
More News

Scholar Rock rocks the boat with new execs—Chutes & Ladders

May 2, 2025 8:30am

FDA pushes back Cytokinetics' heart drug PDUFA to year-end

May 2, 2025 7:48am

Pliant cuts workforce by 45% after bexotegrast trial safety woes

May 2, 2025 7:33am

NIH prohibits grant subawards for international partners

May 1, 2025 5:22pm